Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

NCT03610490 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

16

Enrollment

OTHER

Sponsor class

Stopped Lack of Efficacy

Conditions

Malignant Solid Neoplasm
Metastatic Colorectal Adenocarcinoma
Metastatic Ovarian Carcinoma
Metastatic Pancreatic Ductal Adenocarcinoma
Platinum-Resistant Ovarian Carcinoma
Recurrent High Grade Ovarian Serous Adenocarcinoma
Recurrent Ovarian Carcinosarcoma
Refractory Colorectal Carcinoma
Stage IV Colorectal Cancer AJCC v8
Stage IVA Colorectal Cancer AJCC v8
Stage IVB Colorectal Cancer AJCC v8
Stage IVC Colorectal Cancer AJCC v8

Interventions

BIOLOGICAL: Autologous Tumor Infiltrating Lymphocytes MDA-TIL
DRUG: Cyclophosphamide
DRUG: Fludarabine
BIOLOGICAL: Interleukin-2
OTHER: Quality-of-Life Assessment

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]